Access the full text.
Sign up today, get DeepDyve free for 14 days.
Patricia Hawley, I. Gibson (1996)
Interaction of oligodeoxynucleotides with mammalian cells.Antisense & nucleic acid drug development, 6 3
Pierre Martin (1995)
Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren OligonucleotideHelvetica Chimica Acta, 78
M. Lemaitre, B. Bayard, B. Lebleu (1987)
Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.Proceedings of the National Academy of Sciences of the United States of America, 84 3
C. Stein, L. Neckers, B. Nair, S. Mumbauer, G. Hoke, R. Pal (1991)
Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4.Journal of acquired immune deficiency syndromes, 4 7
C. Majumdar, C. Stein, J. Cohen, S. Broder, S. Wilson (1989)
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide.Biochemistry, 28 3
M. Kulka, C. Smith, L. Aurelian, R. Fishelevich, K. Meade, P. Miller, P. Ts'o (1989)
Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4.Proceedings of the National Academy of Sciences of the United States of America, 86 18
T. Bruice, W. Lima (1997)
Control of complexity constraints on combinatorial screening for preferred oligonucleotide hybridization sites on structured RNA.Biochemistry, 36 16
B. Sproat, A. Iribarren, R. García, B. Beijer (1991)
New synthetic routes to synthons suitable for 2'-O-allyloligoribonucleotide assembly.Nucleic acids research, 19 4
Gilles Parmentier, G. Schmitt, F. Dollé, B. Luu (1994)
A convergent synthesis of 2′-o-methyl uridineTetrahedron, 50
M. Hill, B. Hemmings (2002)
Inhibition of protein kinase B/Akt. implications for cancer therapy.Pharmacology & therapeutics, 93 2-3
C. Stein, Yung‐chi Cheng (1993)
Antisense oligonucleotides as therapeutic agents--is the bullet really magical?Science, 261 5124
Y. Sanghvi, Glenn Hoke, Susan Freier, M. Zounes, Carolyn Gonzalez, L. Cummins, Henri Sasmor, P.Dan Cook (1993)
Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines.Nucleic acids research, 21 14
T. Skorski, Malgorzata Nieborowska‐Skorska, N. Nicolaides, C. Szczylik, Patrick IVERSENt, Renato lozzot, Gerald Zon, Bruno Calabretta (1994)
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.Proceedings of the National Academy of Sciences of the United States of America, 91 10
R. Quartin, C. Brakel, J. Wetmur (1989)
Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates.Nucleic acids research, 17 18
Eliel Bayever, Patrick Iversen, Michael Bishop, J. Sharp, HEMANT Tewary, M. Arneson, Samuel Pirruccello, Raymond Ruddon, A. Kessinger, Gerald Zon, James Armitage (1993)
Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.Antisense research and development, 3 4
R. Crooke (1991)
In vitro toxicology and pharmacokinetics of antisense oligonucleotides.Anti-cancer drug design, 6 6
L. Teresa, Burgess, Eric FISHERt, Sandra Ross, V. James, Breadyt, Y. Qian, Leigh Bayewitchs, Arthur Cohenii, C. Herrera, Sylvia Hu, Tiffin Kramer, D. Fred, Lorlil, F. Martin, G. Pierce, LIZETrE Simonet, Catherine FARRELLt (1995)
The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.Proceedings of the National Academy of Sciences of the United States of America, 92
E. Kuramoto, O. Yano, Y. Kimura, M. Baba, T. Makino, Saburo Yamamoto, Toshiko Yamamoto, T. Kataoka, T. Tokunaga (1992)
Oligonucleotide Sequences Required for Natural Killer Cell ActivationJapanese Journal of Cancer Research : Gann, 83
J. Waters, A. Webb, D. Cunningham, P. Clarke, F. Raynaud, F. Stefano, F. Cotter (2000)
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 9
J. Sheehan, H. Lan (1998)
Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex.Blood, 92 5
A. Grishok, H. Tabara, Craig Mello (2000)
Genetic requirements for inheritance of RNAi in C. elegans.Science, 287 5462
D. Pisetsky, C. Reich (1994)
Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus.Life sciences, 54 2
Leonard Howell, K. Wilcox (2001)
The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates.The Journal of pharmacology and experimental therapeutics, 298 1
Hua-mao Liang, Y. Nishioka, C. Reich, D. Pisetsky, P. Lipsky (1996)
Activation of human B cells by phosphorothioate oligodeoxynucleotides.The Journal of clinical investigation, 98 5
R. Giles, David Spiller, D. Tidd (1995)
Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides.Antisense research and development, 5 1
J. Campbell, T. Bacon, E. Wickstrom (1990)
Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid.Journal of biochemical and biophysical methods, 20 3
M. Ghosh, J. Cohen (1992)
Oligodeoxynucleotides as antisense inhibitors of gene expression.Progress in nucleic acid research and molecular biology, 42
S. Crooke (1992)
Therapeutic Applications of OligonucleotidesBio/Technology, 10
S. Agrawal, J. Goodchild, M. Civeira, A. Thornton, P. Sarin, P. Zamecnik (1988)
Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.Proceedings of the National Academy of Sciences of the United States of America, 85 19
P. O'dwyer, J. Stevenson, M. Gallagher, A. Cassella, I. Vasilevskaya, B. Monia, J. Holmlund, F. Dorr, K. Yao (1999)
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).Clinical cancer research : an official journal of the American Association for Cancer Research, 5 12
Angelo Rosolen, L. Whitesell, N. Ikegaki, R. Kennett, L. Neckers (1990)
Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line.Cancer research, 50 19
S. Pitsch, R. Krishnamurthy, M. Bolli, S. Wendeborn, A. Holzner, M. Minton, Catherine Lesueur, I. Schlönvogt, B. Jaun, A. Eschenmoser (1995)
PYRANOSYL-RNA ('P-RNA') : BASE-PAIRING SELECTIVITY AND POTENTIAL TO REPLICATEHelvetica Chimica Acta, 78
T. Vickers, B. Baker, P. Cook, M. Zounes, R. Buckheit, J. Germany, D. Ecker (1991)
Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element.Nucleic acids research, 19 12
N. Thuong, U. Asseline, T. Montenay‐Garestier (1989)
Oligodeoxynucleotides Covalently Linked to Intercalating and Reactive Substances: Synthesis, Characterization and Physicochemical StudiesChemInform, 23
P. Cossum, L. Truong, S. Owens, P. Markham, J. Shea, S. Crooke (1994)
Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.The Journal of pharmacology and experimental therapeutics, 269 1
P. Gönczy, C. Echeverri, K. Oegema, A. Coulson, Steven Jones, R. Copley, J. Duperon, Jeff Oegema, M. Brehm, Etienne Cassin, E. Hannak, M. Kirkham, S. Pichler, K. Flohrs, Anoesjka Goessen, Sebastian Leidel, Anne-Marie Alleaume, Cécilie Martin, Nurhan Özlü, P. Bork, A. Hyman (2000)
Functional genomic analysis of cell division in C. elegans using RNAi of genes on chromosome IIINature, 408
H. Donis-Keller (1979)
Site specific enzymatic cleavage of RNANucleic acids research, 7 1
R. Burch, M. Weitzberg, N. Blok, R. Muhlhauser, D. Martin, S. Farmer, J. Bator, J. Connor, M. Green, C. Ko (1991)
N-(fluorenyl-9-methoxycarbonyl) amino acids, a class of antiinflammatory agents with a different mechanism of action.Proceedings of the National Academy of Sciences of the United States of America, 88 2
J. Minshull, T. Hunt (1986)
The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations.Nucleic acids research, 14 16
M. Butler, K. Stecker, C. Bennett (1997)
Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.Laboratory investigation; a journal of technical methods and pathology, 77 4
A. Levin, D. Monteith, J. Leeds, P. Nicklin, R. Geary, M. Butler, M. Templin, S. Henry (1998)
Toxicity of Oligodeoxynucleotide Therapeutic AgentsHandbook of experimental pharmacology, 131
R. Yu, R. Geary, J. Leeds, T. Watanabe, M. Moore, J. Fitchett, J. Matson, T. Burckin, M. Templin, A. Levin (2001)
Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.Journal of pharmaceutical sciences, 90 2
Nicholas Dean, R. Mckay (1994)
Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.Proceedings of the National Academy of Sciences of the United States of America, 91 24
M. Mizell, Chapman Hyams, John Smith, Joyce Isaacs (1969)
Interferon Induction Increased through Chemical Modification of a Synthetic PolyribonucleotideScience, 165
Yung‐chi Cheng, Wenqing Gao, F. Han (1991)
Phosphorothioate Oligonucleotides as Potential Antiviral Compounds Against Human Immunodeficiency Virus and Herpes VirusesNucleosides, Nucleotides & Nucleic Acids, 10
W. Lima, V. Mohan, S. Crooke (1997)
The Influence of Antisense Oligonucleotide-induced RNA Structure on Escherichia coli RNase H1 Activity*The Journal of Biological Chemistry, 272
S. Ho, Y. Bao, T. Lesher, Rohit Malhotra, Liyun Ma, S. Fluharty, R. Sakai (1998)
Mapping of RNA accessible sites for antisense experiments with oligonucleotide librariesNature Biotechnology, 16
D. Sokol, Xiaolin Zhang, P. Lu, A. Gewirtz (1998)
Real time detection of DNA.RNA hybridization in living cells.Proceedings of the National Academy of Sciences of the United States of America, 95 20
Aurelio Zerial, N. Thuong, Claude Hélène (1987)
Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent.Nucleic acids research, 15 23
T. Vickers, S. Koo, C. Bennett, S. Crooke, N. Dean, B. Baker (2003)
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense AgentsThe Journal of Biological Chemistry, 278
Y. Sanghvi, P. Cook (1994)
Carbohydrate Modifications in Antisense Research
R. Yu, John Su, J. Grundy, R. Geary, K. Sewell, A. Dorr, A. Levin (2003)
Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens.Antisense & nucleic acid drug development, 13 1
W. Lima, B. Monia, D. Ecker, S. Freier (1992)
Implication of RNA structure on antisense oligonucleotide hybridization kinetics.Biochemistry, 31 48
M. Simons, E. Edelman, J. Dekeyser, R. Langer, R. Rosenberg (1992)
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 359
H. Inoue, A. Imura, E. Ohtsuka (1985)
Synthesis and hybridization of dodecadeoxyribonucleotides containing a fluorescent pyridopyrimidine deoxynucleoside.Nucleic acids research, 13 19
S. Crooke (1998)
Basic Principles of Antisense TherapeuticsHandbook of experimental pharmacology, 131
J. Maier, P. Voulalas, D. Roeder, T. Maciag (1990)
Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer.Science, 249 4976
L. Grillone (2001)
The Development of Antisense Oligonucleotides as Antivirals
M. Graham, S. Freier, R. Crooke, D. Ecker, R. Maslova, E. Lesnik (1993)
Tritium labeling of antisense oligonucleotides by exchange with tritiated water.Nucleic acids research, 21 16
C. Cazenave, C. Stein, N. Loreau, N. Thuong, L. Neckers, C. Subasinghe, C. Hélène, J. Cohen, J. Toulmé (1989)
Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides.Nucleic acids research, 17 11
J. Wyatt, T. Vickers, Joseph Roberson, R. Buckheit, T. Klimkait, Elizabeth DeBaets, P. Davis, B. Rayner, Imbach Louis, D. Ecker (1994)
Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion.Proceedings of the National Academy of Sciences of the United States of America, 91
J. Temsamani, J. Tang, A. Padmapriya, M. Kubert, S. Agrawal (1993)
Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice.Antisense research and development, 3 3
J. Summerton, D. Weller (1997)
Morpholino antisense oligomers: design, preparation, and properties.Antisense & nucleic acid drug development, 7 3
J. Messina, G. Gilkeson, D. Pisetsky (1991)
Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA.Journal of immunology, 147 6
S. Crooke, L. Grillone, A. Tendolkar, Aigin Garrett, M. Fratkin, J. Leeds, W. Barr (1994)
A pharmacokinetic evaluation of 14C‐labeled afovirsen sodium in patients with genital wartsClinical Pharmacology & Therapeutics, 56
Claes Wahlestedt, E. Pich, G. Koob, F. Yee, Markus Heilig, Markus Heilig (1993)
Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides.Science, 259 5094
W. Gao, F. Han, C. Storm, W. Egan, Yung‐chi Cheng (1992)
Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.Molecular pharmacology, 41 2
U. Sarmiento, J. Pérez, J. Becker, R. Narayanan (1994)
In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice.Antisense research and development, 4 2
Ruiwen Zhang, Zhihong Lu, Hui Zhao, Xueshu Zhang, R. Diasio, I. Habuš, Zhiwei Jiang, R. Iyer, Dong Yu, Sudhir Agrawal (1995)
In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.Biochemical pharmacology, 50 4
Susan Wang, R. Lee, G. Cauchon, D. Gorenstein, P. Low (1995)
Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.Proceedings of the National Academy of Sciences of the United States of America, 92
R. Crooke, M. Graham, M. Cooke, S. Crooke (1995)
In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.The Journal of pharmacology and experimental therapeutics, 275 1
A. Sburlati, R. Manrow, S. Berger (1991)
Prothymosin alpha antisense oligomers inhibit myeloma cell division.Proceedings of the National Academy of Sciences of the United States of America, 88 1
M. Hertl, L. Neckers, S. Katz (1995)
Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects.The Journal of investigative dermatology, 104 5
J. Glover, J. Leeds, T. Mant, D. Amin, D. Kisner, J. Zuckerman, R. Geary, A. Levin, W. Shanahan (1997)
Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).The Journal of pharmacology and experimental therapeutics, 282 3
S. Srinivasan, H. Tewary, P. Iversen (1995)
Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin.Antisense research and development, 5 2
M. McManaway, A. al-nasser, B. Shiramizu, W. Goldschmidts, K. Bhatia, I. Magrath, L. Neckers, S. Loke, R. Redner, B. Huber (1990)
Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotideThe Lancet, 335
Hongjiang Wu, W. Lima, S. Crooke (1998)
Molecular cloning and expression of cDNA for human RNase H.Antisense & nucleic acid drug development, 8 1
CM Barton, NR Lemoine (1995)
Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.British Journal of Cancer, 71
R. Burch, L. Mahan (1991)
Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.The Journal of clinical investigation, 88 4
A. Osen‐Sand, M. Catsicas, J. Staple, K. Jones, G. Ayala, J. Knowles, G. Grenningloh, S. Catsicas (1993)
Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivoNature, 364
S. Stepkowski, Xeimei Qu, Mou-Er Wang, L. Tian, Wenhao Chen, E. Wancewicz, J. Johnston, C. Bennett, B. Monia (2000)
INHIBITION OF C-RAF EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES EXTENDS HEART ALLOGRAFT SURVIVAL IN RATS1Transplantation, 70
S. Henry, W. Novotny, J. Leeds, C. Auletta, D. Kornbrust (1997)
Inhibition of coagulation by a phosphorothioate oligonucleotide.Antisense & nucleic acid drug development, 7 5
Peter Frank, Christa Braunshofer-Reiter, Ulrike Wintersberger, Rudolf Grimm, Werner Büsen (1998)
Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII.Proceedings of the National Academy of Sciences of the United States of America, 95 22
Olga Matveeva, Brice Felden, Scott Audlin, Raymond Gesteland, Raymond Gesteland, J. Atkins (1997)
A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures.Nucleic acids research, 25 24
B. Sproat, A. Lamond, B. Beijer, P. Neuner, U. Ryder (1989)
Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases.Nucleic acids research, 17 9
K. Cornish, P. Iversen, Larry Smith, M. Arneson, E. Bayever (1993)
Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey, 3
P. Iversen (1991)
In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue.Anti-cancer drug design, 6 6
Karen Nagel, S. Holstad, K. Isenberg (1993)
Oligonucleotide Pharmacotherapy: An Antigene StrategyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 13
Hong Zhang, J. Cook, J. Nickel, R. Yu, K. Stecker, K. Myers, N. Dean (2000)
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitisNature Biotechnology, 18
B. Baker, L. Miraglia, C. Hagedorn (1992)
Modulation of eucaryotic initiation factor-4E binding to 5'-capped oligoribonucleotides by modified anti-sense oligonucleotides.The Journal of biological chemistry, 267 16
T. Tuschl, P. Zamore, R. Lehmann, D. Bartel, P. Sharp (1999)
Targeted mRNA degradation by double-stranded RNA in vitro.Genes & development, 13 24
S. Henry, J. Zuckerman, J. Rojko, W. Hall, R. Harman, D. Kitchen, S. Crooke (1997)
Toxicological properties of several novel oligonucleotide analogs in mice.Anti-cancer drug design, 12 1
K. Higgins, J. Pérez, T. Coleman, Kenneth Dorshkind, W. Mccomas, Ulla Sarmiento, C. Rosen, R. Narayanan (1993)
Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression.Proceedings of the National Academy of Sciences of the United States of America, 90 21
R. Geary, Tanya Watanabe, L. Truong, Sue Freier, E. Lesnik, N. Sioufi, H. Sasmor, M. Manoharan, A. Levin (2001)
Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.The Journal of pharmacology and experimental therapeutics, 296 3
M. Chiang, H. Chan, Mary Zounes, S. Freier, W. Lima, C. Bennett (1991)
Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.The Journal of biological chemistry, 266 27
A. Gutierrez, T. Terhorst, M. Matteucci, B. Froehler (1994)
5-Heteroaryl-2'-deoxyuridine Analogs. Synthesis and Incorporation into High-Affinity OligonucleotidesJournal of the American Chemical Society, 116
B. Sullenger (2000)
Emerging clinical applications of nucleic acids
C. Novina, M. Murray, D. Dykxhoorn, P. Beresford, J. Riess, Sang-Kyung Lee, R. Collman, J. Lieberman, P. Shankar, P. Sharp (2002)
siRNA-directed inhibition of HIV-1 infectionNature Medicine, 8
P. Ambühl, R. Gyurko, M. Phillips (1995)
A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptorRegulatory Peptides, 59
S. Crooke, K. Lemonidis, L. Neilson, R. Griffey, E. Lesnik, B. Monia (1995)
Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes.The Biochemical journal, 312 ( Pt 2)
G. Hartmann, A. Krug, K. Waller-Fontaine, S. Endres (1996)
Oligodeoxynucleotides Enhance Lipopolysaccharide-Stimulated Synthesis of Tumor Necrosis Factor: Dependence on Phosphorothioate Modification and Reversal by HeparinMolecular Medicine, 2
S. Henry, H. Bolte, C. Auletta, D. Kornbrust (1997)
Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.Toxicology, 120 2
Hongjiang Wu, W. Lima, S. Crooke (1999)
Properties of Cloned and Expressed Human RNase H1*The Journal of Biological Chemistry, 274
Richard Wagner, M. Matteucci, Jason Lewis, A. Gutierrez, C. Moulds, B. Froehler (1993)
Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.Science, 260 5113
B. Weiss, L.-W. Zhou, S.-P. Zhang, Z. Qin (1993)
Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNANeuroscience, 55
P Eder, J Walder (1991)
Ribonuclease H from K562 human erythroleukemia cells. Purification, characterization, and substrate specificity.The Journal of biological chemistry, 266 10
R. Crooke, S. Crooke, M. Graham, M. Cooke (1996)
Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin.Toxicology and applied pharmacology, 140 1
R. Geary, O. Khatsenko, K. Bunker, R. Crooke, M. Moore, T. Burckin, L. Truong, H. Sasmor, A. Levin (2001)
Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.The Journal of pharmacology and experimental therapeutics, 296 3
N. Caplen, S. Parrish, F. Imani, A. Fire, R. Morgan (2001)
Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systemsProceedings of the National Academy of Sciences of the United States of America, 98
B. Monia, J. Johnston, T. Geiger, M. Muller, D. Fabbro (1996)
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinaseNature Medicine, 2
S. Loke, C. Stein, X. Zhang, K. Mori, M. Nakanishi, C. Subasinghe, J. Cohen, L. Neckers (1989)
Characterization of oligonucleotide transport into living cells.Proceedings of the National Academy of Sciences of the United States of America, 86 10
C. Mirabelli, C. Bennett, K. Anderson, S. Crooke (1991)
In vitro and in vivo pharmacologic activities of antisense oligonucleotides.Anti-cancer drug design, 6 6
J. Nyce (1997)
Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases.Expert opinion on investigational drugs, 6 9
N. Dean, R. Mckay, L. Miraglia, R. Howard, S. Cooper, J. Giddings, P. Nicklin, L. Meister, R. Ziel, T. Geiger, M. Müller, D. Fabbro (1996)
Inhibition of Growth of Human Tumor Cell Lines in Nude Mice by an Antisense Oligonucleotide Inhibitor of Protein Kinase C-α ExpressionCancer Research, 56
K. Breslauer, R. Frank, H. Blöcker, L. Marky (1986)
Predicting DNA duplex stability from the base sequence.Proceedings of the National Academy of Sciences of the United States of America, 83 11
T. Nikiforov, Bernard Cornolly (1991)
The synthesis of oligodeoxynucleotides containing 4-thiothymidine residuesTetrahedron Letters, 32
P. Furdon, Z. Dominski, R. Kole
Nucleic Acids Research Nucleic Acids Research
S. Henry, J. Taylor, L. Midgley, A. Levin, D. Kornbrust (1997)
Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.Antisense & nucleic acid drug development, 7 5
R. Joos, W. Hall (1969)
Determination of binding constants of serum albumin for penicillin.The Journal of pharmacology and experimental therapeutics, 166 1
F. Seela, K. Kaiser, U. Bindig (1989)
2′‐Deoxy‐β‐D‐ribofuranosides of N6‐Methylated 7‐Deazaadenine and 8‐Aza‐7‐deazaadenine: Solid‐phase synthesis of oligodeoxyribonucleotides and properties of self‐complementary duplexesHelvetica Chimica Acta, 72
N. Caplen, J. Fleenor, A. Fire, R. Morgan (2000)
dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference.Gene, 252 1-2
P. Nicklin, S. Craig, J. Phillips (1998)
Pharmacokinetic Properties of Phosphorothioates in Animals — Absorption, Distribution, Metabolism and EliminationHandbook of experimental pharmacology, 131
S. Cerritelli, E. Frolova, C. Feng, A. Grinberg, P. Love, R. Crouch (2003)
Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice.Molecular cell, 11 3
J. Hanvey, N. Peffer, J. Bisi, S. Thomson, Rodolfo Cadilla, J. Josey, Daniel Ricca, C. Hassman, M. Bonham, KG Au (1992)
Antisense and antigene properties of peptide nucleic acids.Science, 258 5087
W. Lima, S. Crooke (1997)
Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids.Biochemistry, 36 2
K. Walker, Sherif Elela, R. Nazar (1990)
Inhibition of protein synthesis by anti-5.8 S rRNA oligodeoxyribonucleotides.The Journal of biological chemistry, 265 5
F. Seela, N. Ramzaeva, Yaoming Chen (1995)
Oligonucleotide duplex stability controlled by the 7-substituents of 7-deazaguanine basesBioorganic & Medicinal Chemistry Letters, 5
P. Lin, Daniel M.Brown (1989)
Synthesis and duplex stability of oligonucleotides containing cytosine-thymine analogues.Nucleic acids research, 17 24
Scott Henry, Kim Stecker, Doug Brooks, David Monteith, Boyd Conklin, C. Bennett (2000)
Chemically modified oligonucleotides exhibit decreased immune stimulation in mice.The Journal of pharmacology and experimental therapeutics, 292 2
P. Zamore (2002)
Ancient Pathways Programmed by Small RNAsScience, 296
Long-Wu Zhou, Sui-Po Zhang, Zhen Qin, B. Weiss (1994)
In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.The Journal of pharmacology and experimental therapeutics, 268 2
B. Baker (1993)
Decapitation of a 5'-capped oligoribonucleotide by o-phenanthroline:copper(II)Journal of the American Chemical Society, 115
R. Zhang, R. Diasio, Z. Lu, T. Liu, Z. Jiang, W. Galbraith, S. Agrawal (1995)
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.Biochemical pharmacology, 49 7
N. Dean, R. Mckay, T. Condon, C. Bennett (1994)
Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.The Journal of biological chemistry, 269 23
C. Crum, J. Johnson, A. Nelson, D. Roth (1988)
Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro.Nucleic acids research, 16 10
M. Haeuptle, R. Frank, B. Dobberstein (1986)
Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length.Nucleic acids research, 14 3
S. Agrawal, S. Crooke (1993)
Antisense Research and Applications
J. Hughes, A. Avrutskaya, K. Brouwer, E. Wickstrom, R. Juliano (1995)
Radiolabeling of Methylphosphonate and Phosphorothioate Oligonucleotides and Evaluation of Their Transport in Everted Rat Jejunum SacsPharmaceutical Research, 12
P. Zamecnik, J. Goodchild, Y. Taguchi, P. Sarin (1986)
Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.Proceedings of the National Academy of Sciences of the United States of America, 83 12
J. Leeds, S. Henry, R. Geary, T. Burckin, A. Levin (2000)
Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.Antisense & nucleic acid drug development, 10 6
F. Morvan, B. Rayner, J. Imbach (1991)
Alpha-oligonucleotides: a unique class of modified chimeric nucleic acids.Anti-cancer drug design, 6 6
H. Zheng, B. Sahai, P. Kilgannon, A. Fotedar, D. Green (1989)
Specific inhibition of cell-surface T-cell receptor expression by antisense oligodeoxynucleotides and its effect on the production of an antigen-specific regulatory T-cell factor.Proceedings of the National Academy of Sciences of the United States of America, 86 10
Claes Wahlestedt (1994)
Antisense oligonucleotide strategies in neuropharmacology.Trends in pharmacological sciences, 15 2
G. Hoke, K. Draper, S. Freier, C. González, V. Driver, M. Zounes, D. Ecker (1991)
Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection.Nucleic acids research, 19 20
S. Crooke (2001)
Antisense Drug Technology
H. Sands, L. Gorey-Feret, A. Cocuzza, F. Hobbs, D. Chidester, G. Trainor (1994)
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.Molecular pharmacology, 45 5
M. Nesterova, Y. Cho‐Chung (1995)
A single-injection protein kinase A-directed antisense treatment to inhibit tumour growthNature Medicine, 1
S. Agrawal, X. Zhang, Z. Lu, H. Zhao, J. Tamburin, J. Yan, H. Cai, R. Diasio, I. Habuš, Z. Jiang (1995)
Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.Biochemical pharmacology, 50 4
T. Bacon, François Morvan, B. Rayner, J. Imbach, Eric Wickstrom (1986)
alpha-Oligodeoxynucleotide stability in serum, subcellular extracts and culture media.Journal of biochemical and biophysical methods, 16 4
L. Chrisey, S. Walz, M. Pazirandeh, J. Campbell (1993)
Internalization of oligodeoxyribonucleotides by Vibrio parahaemolyticus.Antisense research and development, 3 4
Jonathan Nyce, W. Metzger (1997)
DNA antisense therapy for asthma in an animal modelNature, 385
L. Neckers (1994)
Cellular Internalization of Oligodeoxynucleotides
R. Walder, J. Walder (1988)
Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.Proceedings of the National Academy of Sciences of the United States of America, 85 14
John Desjardins, John Mata, Tom Brown, Duncan Graham, Gerald Zon, Patrick Iversen (1995)
Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo.Journal of drug targeting, 2 6
P. Miller (1989)
Non-ionic Antisense OligonucleotidesChemInform, 23
S. Agrawal, J. Temsamani, Jin-yang Tang (1991)
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.Proceedings of the National Academy of Sciences of the United States of America, 88 17
David Monteith, Richard Geary, Janet Leeds, Joseph Johnston, Brett Monia, Arthur Levin (1998)
Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.Toxicological sciences : an official journal of the Society of Toxicology, 46 2
Margaret McCarthy, David Nielsen, David Goldman (1995)
Antisense oligonucleotide inhibition of tryptophan hydroxylase activity in mouse brainRegulatory Peptides, 59
David Ecker, Timothy Vickers, TW Bruice, Susan Freier, RD Jenison, Muthiah Manoharan, M. Zounes (1992)
Pseudo--half-knot formation with RNA.Science, 257 5072
P. Zamore, T. Tuschl, P. Sharp, D. Bartel (2000)
RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide IntervalsCell, 101
C. Colby (1971)
The induction of interferon by natural and synthetic polynucleotides.hs.Progress in nucleic acid research and molecular biology, 11
B. Monia, J. Johnston, H. Sasmor, L. Cummins (1996)
Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras*The Journal of Biological Chemistry, 271
A. Quattrone, L. Papucci, N. Schiavone, E. Mini, S. Capaccioli (1994)
Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids.Anti-cancer drug design, 9 6
R. Giles, D. Tidd (1992)
Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures.Nucleic acids research, 20 4
C. Bennett, M. Chiang, H. Chan, S. Grimm (1993)
Use of Cationic Lipids to Enhance the Biological Activity of Antisense OligonucleotidesJournal of Liposome Research, 3
L. Whitesell, Angelo Rosolen, L. Neckers (1991)
In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide.Antisense research and development, 1 4
J. Hall, D. Hüsken, U. Pieles, H. Moser, R. Häner (1994)
Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides.Chemistry & biology, 1 3
S. Crooke, Mark Graham, Joan Zuckerman, D. Brooks, B. Conklin, L. Cummins, Michael Greig, C. Guinosso, D. Kornbrust, Muthiah Manoharan, H. Sasmor, T. Schleich, K. Tivel, Rich Griffey (1996)
Pharmacokinetic properties of several novel oligonucleotide analogs in mice.The Journal of pharmacology and experimental therapeutics, 277 2
C. Bennett, M. Chiang, H. Chan, J. Shoemaker, C. Mirabelli (1992)
Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.Molecular pharmacology, 41 6
L. Cowsert, M. Fox, G. Zon, C. Mirabelli (1993)
In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital wartsAntimicrobial Agents and Chemotherapy, 37
W. Galbraith, W. Hobson, P. Giclas, P. Schechter, S. Agrawal (1994)
Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey.Antisense research and development, 4 3
Scott Henry, Patricia Giclas, Janet Leeds, M. Pangburn, Carol Auletta, Arthur Levin, Douglas Kornbrust (1997)
Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.The Journal of pharmacology and experimental therapeutics, 281 2
J. Nemunaitis, J. Holmlund, M. Kraynak, D. Richards, J. Bruce, N. Ognoskie, Kwoh Tj, Richard Geary, A. Dorr, D. Hoff, S. Eckhardt (1999)
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 11
A. Kawasaki, M. Casper, S. Freier, E. Lesnik, M. Zounes, L. Cummins, Carolyn Gonzalez, P. Cook (1993)
Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.Journal of medicinal chemistry, 36 7
B. Monia, E. Lesnik, Carolyn Gonzalez, W. Lima, D. McGee, C. Guinosso, A. Kawasaki, P. Cook, S. Freier (1993)
Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression.The Journal of biological chemistry, 268 19
P. Nicklin, J. Ambler, A. Mitchelson, D. Bayley, J. Phillips, S. Craig, B. Mania (1997)
Preclinical Profiling of Modified Oligonucleotides: Anticoagulation and Pharmacokinetic PropertiesNucleosides, Nucleotides & Nucleic Acids, 16
L. Tao, K. Marx, W. Wongwit, Z. Jiang, S. Agrawal, R. Coleman (1995)
Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by Schistosoma mansoni.Antisense research and development, 5 2
Ruiwen Zhang, Jieming Yan, H. Shahinian, Girish Amin, Zhihong Lu, Tiepu Liu, M. Saag, Zhiwei Jiang, J. Temsamani, R. Martin, P. Schechter, S. Agrawal, R. Diasio (1995)
Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV‐infected subjectsClinical Pharmacology & Therapeutics, 58
Mike Templin, A. Levin, M. Graham, P. Åberg, B. Axelsson, Madeline Butler, Richard Geary, C. Bennett (2000)
Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice.Antisense & nucleic acid drug development, 10 5
Z. Qin, L. Zhou, S. Zhang, Y. Wang, B. Weiss (1995)
D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.Molecular pharmacology, 48 4
Z. Dominski, R. Kole (1993)
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.Proceedings of the National Academy of Sciences of the United States of America, 90 18
C. Gagnor, J. Bertrand, S. Thenet, M. Lemaitre, F. Morvan, B. Rayner, C. Malvy, B. Lebleu, J. Imbach, C. Paoletti (1987)
α-DNA VI: comparative study of α- and β-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibitionNucleic Acids Research, 15
S. Crooke (1993)
Progress toward oligonucleotide therapeutics: pharmacodynamic propertiesThe FASEB Journal, 7
C. Smith, L. Aurelian, M. Reddy, P. Miller, P. Ts'o (1986)
Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.Proceedings of the National Academy of Sciences of the United States of America, 83 9
G. Hartmann, A. Krieg (2000)
Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1The Journal of Immunology, 164
Jun-ichi Abe, Wei Zhou, Jun Taguchi, N. Takuwa, Keisaburo Miki, Hiroshi Okazaki, Kiyoshi Kurokawa, Mamoru Kumada, Yoh Takuwa (1994)
Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery.Biochemical and biophysical research communications, 198 1
M. Graham, S. Crooke, D. Monteith, S. Cooper, K. Lemonidis, K. Stecker, Michael Martin, R. Crooke (1998)
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.The Journal of pharmacology and experimental therapeutics, 286 1
W. Lima, S. Crooke (1997)
Cleavage of Single Strand RNA Adjacent to RNA-DNA Duplex Regions by Escherichia coli RNase H1*The Journal of Biological Chemistry, 272
Y. Takakura, R. Mahato, M. Yoshida, T. Kanamaru, M. Hashida (1996)
Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system.Antisense & nucleic acid drug development, 6 3
Nobuko Hijiya, Jin Zhang, M. Ratajczak, Jeffrey Kant, Kim Deriel, M. Herlyn, Gerald Zon, A. Gewirtz (1994)
Biologic and therapeutic significance of MYB expression in human melanoma.Proceedings of the National Academy of Sciences of the United States of America, 91 10
T. Wallace, S. Bazemore, D. Kornbrust, P. Cossum (1996)
Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.The Journal of pharmacology and experimental therapeutics, 278 3
G. Vasanthakumar, N. Ahmed (1989)
Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates.Cancer communications, 1 4
S. Henry, D. Monteith, A. Levin (1997)
Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.Anti-cancer drug design, 12 5
H. Sands, L. Gorey-Feret, S. Ho, Y. Bao, A. Cocuzza, D. Chidester, F. Hobbs (1995)
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.Molecular pharmacology, 47 3
C. Hélène, J. Toulmé (1989)
Control of Gene Expression by Oligodeoxynucleotides Covalently Linked to Intercalating Agents and Nucleic Acid-cleaving Reagents
P. Zamecnik, M. Stephenson (1978)
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.Proceedings of the National Academy of Sciences of the United States of America, 75 1
K. Lin, Robert Jones, M. Matteucci (1995)
Tricyclic 2'-Deoxycytidine Analogs: Syntheses and Incorporation into Oligodeoxynucleotides Which Have Enhanced Binding to Complementary RNAJournal of the American Chemical Society, 117
P. Cossum, H. Sasmor, D. Dellinger, L. Truong, L. Cummins, S. Owens, P. Markham, J. Shea, S. Crooke (1993)
Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.The Journal of pharmacology and experimental therapeutics, 267 3
C. Gagnor, B. Rayner, J. Leonetti, J. Imbach, Bernard Leblcu (1989)
α-DNA IX: parallel annealing of α-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcriptionNucleic Acids Research, 17
S. Der, Yi‐Li Yang, C. Weissmann, B. Williams (1997)
A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis.Proceedings of the National Academy of Sciences of the United States of America, 94 7
Isao Kitajima, Toshiya Shinohara, James Bilakovics, David Brown, Xiao Xu, Michael Nerenberg (1992)
Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B.Science, 259 5101
Sayda Elbashir, J. Harborth, Winfried Lendeckel, A. Yalçin, K. Weber, T. Tuschl (2001)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cellsNature, 411
L. Griffin, G. Tidmarsh, L. Bock, J. Toole, L. Leung (1993)
In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits.Blood, 81 12
S. Saxena, E. Ackerman (1990)
Microinjected oligonucleotides complementary to the alpha-sarcin loop of 28 S RNA abolish protein synthesis in Xenopus oocytes.The Journal of biological chemistry, 265 6
K. Katayanagi, M. Okumura, K. Morikawa (1993)
Crystal structure of Escherichia coli RNase HI in complex with Mg2+ at 2.8 Å resolution: Proof for a single Mg2+‐binding siteProteins: Structure, 17
S. Henry, L. Grillone, J. Orr, R. Bruner, D. Kornbrust (1997)
Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.Toxicology, 116 1-3
B. Yacyshyn, M. Bowen-Yacyshyn, L. Jewell, J. Tami, C. Bennett, D. Kisner, W. Shanahan (1998)
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.Gastroenterology, 114 6
S. Kanaya, C. Katsuda-Nakai, M. Ikehara (1991)
Importance of the positive charge cluster in Escherichia coli ribonuclease HI for the effective binding of the substrate.The Journal of biological chemistry, 266 18
A. Krieg, A. Yi, S. Matson, T. Waldschmidt, G. Bishop, R. Teasdale, G. Koretzky, D. Klinman (1995)
CpG motifs in bacterial DNA trigger direct B-cell activationNature, 374
T. Fredriksson, U. Pettersson (1978)
Severe psoriasis--oral therapy with a new retinoid.Dermatologica, 157 4
R. Azad, V. Driver, K. Tanaka, R. Crooke, K. Anderson (1993)
Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early regionAntimicrobial Agents and Chemotherapy, 37
J. Rappaport, B. Hanss, J. Kopp, T. Copeland, L. Bruggeman, T. Coffman, P. Klotman (1995)
Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy.Kidney international, 47 5
S. Zhang, L. Zhou, B. Weiss (1994)
Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.The Journal of pharmacology and experimental therapeutics, 271 3
J. SantaLucia, R. Kierzek, D. Turner (1991)
Functional group substitutions as probes of hydrogen bonding between GA mismatches in RNA internal loopsJournal of the American Chemical Society, 113
Alan Yuen, J. Halsey, George Fisher, Jon Holmlund, Richard Geary, T. Kwoh, Andrew Dorr, B. Sikic (1999)
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 11
T. Miyao, Y. Takakura, T. Akiyama, F. Yoneda, H. Sezaki, M. Hashida (1995)
Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice.Antisense research and development, 5 2
P. Westermann, B. Gross, G. Hoinkis (1989)
Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides.Biomedica biochimica acta, 48 1
A. Fraser, R. Kamath, Peder Zipperlen, Maruxa Martínez‐Campos, M. Sohrmann, J. Ahringer (2000)
Functional genomic analysis of C. elegans chromosome I by systematic RNA interferenceNature, 408
H. Davis, Risini Weeranta, T. Waldschmidt, L. Tygrett, J. Schorr, A. Krieg (1998)
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.Journal of immunology, 160 2
F. Martin, Miguel Castro, F. Aboul-ela, Ignacio Tinoco (1985)
Base pairing involving deoxyinosine: implications for probe design.Nucleic acids research, 13 24
R. Zhang, Z. Lu, X. Zhang, H. Zhao, R. Diasio, T. Liu, Z. Jiang, S. Agrawal (1995)
In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.Clinical chemistry, 41 6 Pt 1
L. Maher, Barbara Wold, P. Dervan (1989)
Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation.Science, 245 4919
Antisense technology exploits oligonucleotide analogs to bind to target RNAs via Watson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradation of the target RNA. Antisense agents can also alter splicing. During the past decade, much has been learned about the basic mechanisms of antisense, the medicinal chemistry, and the pharmacologic, pharmacokinetic, and toxicologic properties of antisense molecules. Antisense technology has proven valuable in gene functionalization and target validation. With one drug marketed, Vitravene™, and approximately 20 antisense drugs in clinical development, it appears that antisense drugs may prove important in the treatment of a wide range of diseases.
Annual Review of Medicine – Annual Reviews
Published: Feb 18, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.